Compare IPSC & MDAI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | IPSC | MDAI |
|---|---|---|
| Founded | 2019 | 2013 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medicinal Chemicals and Botanical Products | Medical/Dental Instruments |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 58.3M | 47.6M |
| IPO Year | 2021 | N/A |
| Metric | IPSC | MDAI |
|---|---|---|
| Price | $0.92 | $1.62 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 6 | 2 |
| Target Price | $3.00 | ★ $3.25 |
| AVG Volume (30 Days) | ★ 1.5M | 290.9K |
| Earning Date | 11-13-2025 | 11-11-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $113,337,000.00 | $23,168,000.00 |
| Revenue This Year | $1,590.09 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 4122.69 | N/A |
| 52 Week Low | $0.34 | $1.04 |
| 52 Week High | $1.19 | $3.21 |
| Indicator | IPSC | MDAI |
|---|---|---|
| Relative Strength Index (RSI) | 61.52 | 54.71 |
| Support Level | $0.91 | $1.41 |
| Resistance Level | $1.05 | $1.47 |
| Average True Range (ATR) | 0.12 | 0.08 |
| MACD | 0.01 | 0.02 |
| Stochastic Oscillator | 66.72 | 91.07 |
Century Therapeutics Inc is a biotechnology company that specializes in leveraging adult stem cells to develop cell therapy products aimed at treating cancer, autoimmune disorders, and inflammatory diseases. Their features a genetically engineered allogeneic cell therapy platform that incorporates induced pluripotent stem cells (iPSCs), CRISPR-mediated precision gene editing, proprietary chimeric antigen receptors (CARs), Allo-EvasionTM technology, and manufacturing capabilities. This comprehensive platform seeks to address the limitations of first-generation cell therapies by optimizing cell product performance, preventing rejection by the host immune system, and reducing development and supply risks.
Spectral AI Inc is an AI company, focused on predictive medical diagnostics. Spectral is devoting substantially all of its efforts towards the research and development of its DeepView System, an internally developed MSI device that has designated FDA BDD status. Its DeepView System uses proprietary algorithms to distinguish between damaged and healthy human tissue invisible to the naked eye, providing Day One healing assessments in seconds. The Company's output is specifically engineered to allow the physician to make a more accurate, timely, and informed decision regarding the treatment of the patient's wound.